NCT01106014

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,156 (actual)
• Sponsor: Actelion · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.

Conditions

• Pulmonary Arterial Hypertension

Interventions

Type	Name	Description
DRUG	Selexipag	Selexipag 200 µg tablets
DRUG	Placebo	Placebo tablets matching selexipag

Timeline

• Start date: 2009-12-01
• Primary completion: 2014-04-01
• Completion: 2014-10-01
• First posted: 2010-04-19
• Last updated: 2025-10-27
• Results posted: 2016-03-01

Locations

182 sites across 39 countries: United States, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, Peru, Poland, Romania, Russia, Serbia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom